Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amylin receptor agonist monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- iBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
iBio Inc., in partnership with AstralBio, is developing an engineered monoclonal antibody that acts as an amylin receptor agonist for the treatment of obesity and cardiometabolic diseases. This preclinical-stage candidate is designed to selectively activate the amylin receptor, a target that regulates satiety and delays gastric emptying. Unlike traditional peptide-based amylin agonists, this antibody-based approach aims to provide a longer half-life, allowing for less frequent dosing and potentially improved tolerability. In preclinical mouse models of obesity, the antibody demonstrated a 60% reduction in acute food intake, showing efficacy comparable to established peptide-based amylin agonists. The program is part of iBio's AI-driven discovery pipeline targeting genetically validated pathways in cardiometabolic health.
- Other names
- Amylin AntibodyiBio amylin antibodyengineered amylin receptor agonist monoclonal antibody
02
Targets
AMY receptor (Calcitonin receptor (with ramps))
Beyond the preview
Go deeper on amylin receptor agonist monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amylin receptor agonist monoclonal antibody.